Abstract -This paper demonstrates the ability of machine learning approaches to identify a few genes among the 23,398 genes of the human genome to experiment on in the laboratory to establish new drug mechanisms. As a case study, this paper uses MDA-MB-231 breast cancer singlecells treated with the antidiabetic drug metformin. We show that mixture-model-based unsupervised methods with validation from hierarchical clustering can identify single-cell subpopulations (clusters). These clusters are characterized by a small set of genes (1% of the genome) that have significant differential expression across the clusters and are also highly correlated with pathways with anticancer effects driven by metformin. Among the identified small set of genes associated with reduced breast cancer incidence, laboratory experiments on one of the genes, CDC42, showed that its downregulation by metformin inhibited cancer cell migration and proliferation, thus validating the ability of machine learning approaches to identify biologically relevant candidates for laboratory experiments. Given the large size of the human genome and limitations in cost and skilled resources, the broader impact of this work in identifying a small set of differentially expressed genes after drug treatment lies in augmenting the drug-disease knowledge of pharmacogenomics experts in laboratory investigations, Manuscript received May 14, 2017; accepted May 14, 2018 
which could help establish novel biological mechanisms associated with drug response in diseases beyond breast cancer.
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I. INTRODUCTION

P
OPULATION studies have shown that an anti-diabetic drug called metformin inhibits cancer growth in various types of cancer, including triple-negative breast cancer [2] , [3] . Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer that does not have any standard targeted therapies [4] , [5] . Pharmacogenomics research focuses on understanding the interplay between drug effects and functions of the genome (i.e., human DNA). Using the example of metformin response in TNBC, this work shows that when biomarkers of drug response are not known a priori, it is possible for unsupervised learning methods to augment pharmacogenomics experts' knowledge by identifying a few genes, out of the entire human genome (i.e., 23, 398 genes), as candidates for laboratory experiments to establish novel biological mechanisms of a drug.
The purpose of the overall project driving this paper is to use machine learning methods to help infer the molecular mechanism by which metformin inhibits cancer growth in TNBC. The workflow of our analysis is illustrated in Fig. 1 . In order to identify metformin's impact on the TNBC cells, we used two identical MDA-MB-231 TNBC cell populations, including 192 cells (2 assays, each comprising 96 cells) not treated with metformin (referred to as baseline cells), and an equal number of the same cells treated with metformin (referred to as metformin-treated cells). We sequenced the cells by using single-cell RNA sequencing (scRNA-seq) technology, and the resulting data comprise the expression measure for each gene of the sequenced genome contained in each of the cells under study [6] . The data reflect 23, 398 genes and their associated gene expressions for baseline and metformin-treated cells. Thus, the overall data consist of 9M 1 gene expression values. The goal of the analytics in this work was to infer clusters of metformin-treated cells by using unsupervised learning and then identify a small group of differentially expressed genes 1 [192*2 cells]*23, 398 ≈ 9M.
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See http://www.ieee.org/publications_standards/publications/rights/index.html for more information. across clusters. Those genes can then be used to identify associated diseases and pathways (where a pathway is a "series of actions among molecules in a cell that leads to a certain product or a change in the cell") 2 by performing pathway analysis. By combining differentially expressed genes that overlap with relevant pathways (as found by our pathway analysis) and available data on these genes from the existing literature in the context of metformin and anticancer mechanisms, we choose genes that have been implicated as having anticancer functions as candidates for laboratory experiments.
In this work, we used mixture-model-based clustering, hierarchical clustering, and k-means clustering as unsupervised learning methods. Based on the observations of multiple normal distributions in gene expressions of single cells (see Sec. III and Fig. 2) , we first used a mixture-modelbased unsupervised learning approach embodied in a tool we created called MiMoSA, for "mixture-model-based singlecell analyses" (described in Sec. IV-A) [1] . MiMoSA found 310 of the 23, 398 genes to be significantly differentially expressed in six metformin-treated cells. As a validating step for MiMoSA's findings, hierarchical clustering approaches (divisive and agglomerative clustering) also identified the same set of 310 differentially expressed genes identified by MiMoSA (see Sec. IV-B). However, the unsupervised and lightly supervised approaches using k-means clustering for a range of k = [2 : 9] were unable to find a set of clusters that could either identify the same set of 310 differentially expressed genes found by MiMoSA and hierarchical clustering, or identify a different set of differentially expressed genes (see Sec. IV-D).
That set of 310 genes is small enough to be handled by well-understood bioinformatics approaches, such as pathway analysis. As a substantiation of our learning approach, pathway analysis of the downregulation of these 210 genes showed strong correlations with three pathways: i) oxidative phos-phorylation (p-value 3.81E − 21), ii) the citric acid (TCA) cycle (p-value 2.10E − 19), and iii) the respiratory electron transport and mitochondrial translation (p-value 1.41E − 07). All of those pathways were recently found to have anticancer properties, via both in-vivo and in-vitro experiments [7] - [10] . Further, among the differentially expressed genes that overlap with those pathways, we have identified the NDUFB9, COX5B, MRPS7, and CDC42, which have been implicated in other anticancer mechanisms for other cancers not driven by metformin; these genes are now candidates for laboratory experiments. In Sec. V, we present a summary of laboratory experiments on CDC42's downregulation by metformin that explain the inhibition of cell migration and cell proliferation in triple-negative breast cancer [11] . Results from the laboratory experiments demonstrate the power of unsupervised learning that can not only identify candidate genes for laboratory experiments, but also identify genes that could lead to the establishment of novel mechanisms of drug action.
Traditional bulk sequencing enabled the study of aggregate gene expressions in a tumor sample. However, with scRNA-seq, the amount of data is significantly larger, and we have gained finer differentiation of cells by using distributions of gene expression in the cells, as opposed to the single aggregate value of gene expression provided by bulk sequencing. For example, scRNA-seq generates about 1 million RNA sequences per cell comprising roughly 24, 000 genes. When two sequencing panels are analyzed, where each panel consists of 96 cells, 192M sequences are generated (see Fig. 1 ). Several prior efforts (discussed in Sec. II) have analyzed single-cell data, but our work is unique in that it demonstrates the ability of data-driven unsupervised learning analytics to help establish novel biological mechanisms.
Key additional contributions of this work are as follows. 1) We demonstrate the feasibility of using learning methods to inform novel biology: This work demonstrates the complete workflow of analyses that proceed from data generation, to machine learning analyses, to laboratory experiments, and finally to identifying novel mechanisms of drug action in triple negative breast cancer (see Sec. V). This work represents a significant advancement considering that the molecular mechanisms of metformin's response in TNBC are not yet known. 2) Test dataset and tool access: We provide access to a test dataset and MiMoSA, which is compatible with multiple operating systems and computation architectures.
II. RELATED WORK
The recently proposed methods for analyzing single-cell data have largely focused on finding subpopulations of cells in a population of cells [12] , [13] . All of the proposed methods include two steps of processing, first reducing the number of genes being used to cluster cells, and then using a clustering method to find subpopulations of cells. Further, all these methods have found that only a few thousand genes are significantly differentially expressed in cell samples [12] - [14] . For the second step of these analyses, supervised, unsupervised, or graphical model approaches [14] are used.
The first step of the analysis tries to retain the genes that show variation in their expression levels across the samples. For example, in the transcriptome analysis of lung adenocarcinoma [12] , the method to reduce the dimensionality of the data (for genes in this context) was to start by looking at genes (expressed across all the samples) whose gene expressions were measured as greater than 0, thereby reducing the gene list to about 9, 000 genes. Then, the authors of [12] studied the correlation of gene expression among these genes by using Pearson's correlation analysis, and reduced the gene list to about 5, 500 genes by choosing genes with correlation coefficients greater than 0.9. In an analysis of cellto-cell heterogeneity that revealed subpopulations [13] , prior knowledge of cell-cycle genes was used, and only genes that showed significant correlation were chosen, bringing the gene list down from 23, 398 to 2, 881.
To reduce the number of genes needed to infer cell types (assuming that the data are normally distributed), sharednearest neighbors (SNN) or k-means clustering is used [14] . In particular, when SNN is used on simulated and real cell data, it has been shown that it performs better than k-means clustering when no biological priors are used [14] . However, there remains an open problem on how to choose the optimal number of neighbors and k values; currently, we must perform an extensive search of values or use heuristics to estimate the best values. One particular approach that is different from the normal two-step process is the use of diffusion maps [15] , a supervised approach. Haghverdi et al. [15] assume the existence of known types of cells and then use a transition matrix for classifying cells based on the state they best match their signature to. To do so, the authors needed to define the Gaussian kernel and further approximate the transition probabilities, and those steps are hinged on the assumption that the cell types are known.
A significant number of single-cell analyses have used hierarchical clustering [16] , [17] to infer cell heterogeneity and then determine whether the inferred clusters matched with known cell types inferred using human observation (e.g., pathology) [18] - [20] . While making no implicit assumptions on the data's distribution, these works have identified several novel mechanisms in the context of circulating tumor cells, preimplantation embryos and embryonic stem cells, and phospho-protein networks in cancer cells among other studies.
All the aforementioned methods for single-cell analysis are driven either by implicit assumptions in normality, known correlations between genes and biological mechanisms, or by supervised methods that use cell signatures. However, in problems where either there are many mechanisms related to drug response or we do not know the mechanism by which the drug impacts the cells, we have to turn to data-driven methods that first study characteristics of the data and then choose a method/algorithm to apply on the data. Further interpretation of the chosen method's results requires interactions with domain experts to address the primary goal of the analysis. To the best of our knowledge, no methods exist that can use mixture-model distributions to infer clusters of cells, despite the observation that gene expression of cells is best described using mixture models.
Through 1) prior methodological innovations presented in describing MiMoSA [1] to cluster cells whose gene expressions are characterized as a mixture of Gaussians, 2) novel biological mechanisms of metformin in TNBC established using candidate genes identified by MiMoSA [11] , and 3) additional methodological investigations presented in this work to identify novel candidates for laboratory experiments, multiple research gaps are addressed in our work that have been overlooked by previous analysis methods. 1) Our case study demonstrates a consistent method to go from data generation from drug intervention, to identifying major candidates for focused laboratory experimentation to establish a drug's molecular mechanisms. 2) Our work does not make prior assumptions on gene correlations with drug response to reduce the number of genes for analysis. 3) Our choice of method was driven by observations made in our preliminary analysis, which revealed that distributions of gene expression in cells were best described by mixtures of Gaussians; this observation was aided by the fine resolution of data provided by scRNA-seq.
III. DATA AND DATA CHARACTERISTICS
A. Data
The MDA-MB-231 breast cancer cell line (ATCC HTB-26) was cultured in Leibovitz's L-15 medium with 10% fetal bovine serum for 5 days with and without metformin. Duplicate cultures were processed for single-cell analysis. Single cells with and without metformin were captured on a large-sized (17−25μm cell diameter) microfluidic mRNA-seq chip known as the C1 Single-Cell Auto Prep IFC, using the C T M Single-Cell Auto Prep System (Fluidigm Corporation, South San Francisco, CA). Cells were loaded onto the chips at a concentration of 300 cells/μl, stained for viability with a LIVE/DEAD cell viability assay kit (Life Technologies, Carlsbad, CA), and imaged by phase contrast and fluorescence microscopy to assess the number and viability of cells per capture site. Only single, live cells were included in the analysis. cDNAs were prepared on-chip using the SMARTer Ultra Low RNA kit for Illumina (Clontech Laboratories, Mountain View, CA). Single-cell cDNA size distribution and concentration were measured with a Quant-iT Pico green dsDNA assay kit (Life Technologies). Illumina libraries were constructed in 96-well plates using the Illumina Nextera XT DNA Sample Preparation kit using the protocol supplied by Fluidigm. Libraries were quantified by Agilent BioAnalyzer, using a high-sensitivity DNA analysis kit. Single-cell Nextera XT (Illumina) libraries of one experiment were pooled and sequenced at 100 bp paired-end on Illumina Hiseq to a depth of about 1 million reads. Single-cell mRNA-Seq data were processed using the MAP-Rseq pipeline [21] .
B. Data Characteristics and Pre-Processing
The data characteristics are as follows. 1) The data comprises 192 baseline cells, and an equal number of cells treated with metformin. 23, 398 genes were sequenced in each cell, and MAP-Rseq [21] was used to obtain gene expressions from sequencing data. 2) The expression value for each gene was normalized by accounting for the sequencing depth (number of short DNA sequence strings from the sequencing platform aligned to a gene) and length of the gene. The unsupervised learning view of single-cell analysis is explained as follows. Cells exposed to a drug may exhibit differences in their gene expression behavior due to the molecular interactions with the drug, and these differences are not known. The computational problem is to cluster these cells (samples), and extract the genes (features) that are behaving differently compared to other clusters (referred to as differentially expressed genes). These differentially expressed genes are analyzed to study their biological significance in all known disease and molecular pathways.
of 0.05, thereby failing to reject the null hypothesis, meaning that the model fit was statistically close to the actual data's distribution. 6) In some metformin-treated cells, at least one component of the mixture had phase-shifted significantly. Therefore, metformin was affecting these cells differently from other cells, thereby making the drug's effect on the cells non-uniform, as shown in Fig. 2(c) . We observed that 80% of the genes were considered inactive in the data, and as our focus in this analysis was on the impact of metformin measured by changes in gene expression, only genes in the top 5% of variance across cells were considered. That narrowing of the data set reduced the number of genes (features) for our analysis from 23, 398 to 1, 170. We used the reduced set of genes and the samples as inputs to the unsupervised learning methods. This way of reducing feature space is common in bioinformatics practices, although there is no standard threshold for the amount of variance to consider in gene expression profiles. The general assumption is that only a few biological pathways, comprising 100 -400 genes, are affected by a treatment, and thus these genes would very likely be present within the top 5% most variable genes.
IV. METHODS AND RESULTS
We describe the approaches used to analyze single cells with an unsupervised learning approach as shown in Fig. 3 ,
Analytical Approach and Visualization
Our overarching analytical approach was to begin with a method that best suited the data characteristics and the method's assumptions. Hence, we first began with mixturemodel-based unsupervised learning embodied in MiMoSA, given the observation that distribution of gene expressions in a single-cell population is a mixture of multiple distributions. Then, assuming that cell distributions are characterized by a few differentially expressed genes, we used hierarchical clustering approaches to verify the clusters. We chose that approach because the clusters are formed based on similarity in Euclidean distances; hence, if the expression of a few genes is sufficient to cluster cells into groups, then hierarchical clustering could, in theory, capture cell clusters that are highly concordant with those found by MiMoSA. Finally, for a range of k, we chose k-means clustering to assess whether the inferred clusters captured the same differentially expressed genes identified by MiMoSA.
Since scRNA-seq allows one to study the expression of the genome in each cell, it would also be of interest to visualize the subpopulations (i.e., inter-cluster separations) inferred using single-cell analyses. Earlier efforts have used either linear methods, such as principal component analysis (PCA) [22] , or nonlinear methods such as t-distributed stochastic neighbor embedding (t-SNE) [23] to reduce the dimensionality of the data to two or three dimensions, and then projected the clusters onto these lower dimensions [14] , [24] . Our prior work demonstrating the clustering capabilities of MiMoSA showed that projection of the cluster labels onto the first two principal components computed using PCA helped visualize cluster separations better than t-SNE did [1] . Hence, we demonstrate the inter-cluster separation using only PCA in this work.
A. Inferring Cell Subpopulations
MiMoSA: Based on our knowledge of the presence of multiple distributions in our data, as illustrated in Fig. 2 , we chose to use probability distribution models to cluster the cells. Probability models cluster data according to a model (distribution) that best defines the data (such as Gaussian mixture models, in this work), and treats each sample (cell) as being independent from other samples. The assumption of independence is acceptable, since each cell can behave differently and independently of other cells in response to metformin. We define the likelihood L i of the mixture model for each cell y i of N cells as shown in Equation 1, where there are K mixtures/components, f k is the distribution of the component k, and θ k is the distribution's parameters.
We chose to fit the data with Gaussian mixture models (GMM) with varying volumes and finite mixtures, as this provided the best likelihood score for fitting the data. In (a) and (b), we project, respectively, the baseline and metformin-treated cell clusters found by MiMoSA onto the first two principal components derived from PCA.
The multivariate Gaussian distribution function is as defined in Equation 2
, where (μ k , k ) is the mean and covariance of the component k. Because our model has mixtures of Gaussians, we need to compute the model parameters using the maximum likelihood (ML). For model estimation, there are two popular algorithms to choose from: the expectation maximization algorithm (EM), and the variational Bayesian EM algorithm (VBEM). Both algorithms are iterative and are known to have similar time complexities; VBEM can be used to perform automatic model selection and is less prone to over-fitting than is EM. However, implementations of VBEM required binning of the gene expression measures, and with small sample space and large variation in the range of gene expression, the binning proved to be a challenge. Hence, we used the EM algorithm for ML to learn the model parameters. The EM algorithm is a two-step process. First, the E-step computes the conditional expectation of the observable data and current parameter estimate. Then, the M −step maximizes the log-likelihood of the parameter estimates learned in the E-step.
Once we have learned the model parameters, we then need to decide on an optimal number of clusters. One method that has historically provided a consistent estimator of the number of clusters is Bayesian information criteria (BIC) [25] , where the value of K at which the BIC value asymptotically converges is chosen. We implemented the model-based clustering from the "mclust" package in R [26] . MiMoSA identified two clusters (B1,B2) in baseline cells, and three clusters (M1, M2,M3) in metformin-treated cells. The clustering visualizations obtained using PCA for baseline and metformintreated cells are shown in Figs. 4(a)-4(b) . We observe that 
B. Cluster Validation: Hierarchical Clustering
We validated the clusters inferred by MiMoSA by using hierarchical clustering methods. We performed both agglomerative and divisive hierarchical clustering on metformin-treated cells. Hierarchical clustering was chosen because it is based on comparison of pairwise similarity of features. Principal component analysis of metformin-treated cells showed that 97% of the variability was captured within the first two components. Thus, it is likely that a few genes are probably significantly altered by metformin, while the rest of the genes show little change in their expression. Hence, pairwise comparison of the cells would tend to cluster cells with similar changes in the expression of the genome.
Hierarchical clustering treated each of the N cells as a data point described by a set of M feature coordinates, where each individual feature coordinate is the expression of a gene. We computed the relative measure of proximity between the cells that encompassed all of the M gene expression levels. We performed agglomerative clustering through successive merging of N total clusters, based on proximity, into a single, global cluster. We performed divisive clustering in the inverse direction, which is to begin with a single cluster (comprising all N cells) and successively splitting it into N remaining clusters. We performed agglomerative and divisive hierarchical clustering on the metformin-treated cells using the proximity matrix and complete linkage; the details have been previously published [1] . We began pruning the clustering hierarchy from both approaches by starting from the root until we arrived at three sub-trees (clusters). We note the similarity among the numbers of cells present the three main clusters, shown in Table I . Further, we find that all the cells in cluster 2 of both hierarchical methods overlapped with M2 from MiMoSA, with M2 having one additional cell. Thereby, we found that clusters inferred by MiMoSA were validated by at least one other clustering approach with a different mathematical formalism, such as one of those used in hierarchical clustering methods. Given the evidence of cluster replication in these independent methods, we proceeded to analyze the clusters to identify a set of genes that are differentially expressed across these clusters.
C. Cluster Analysis
The clusters inferred by MiMoSA in metformin-treated cells are characterized by 310 differentially expressed genes of which about 200 are downregulated and about 100 are upregulated in cluster M2, compared to M1 and M3.
Clusters M1 and M3 showed little variation in gene expression, and the cells comprising cluster M2 were the most affected by metformin having a striking downregulation of over 200 genes, as shown in Fig. 5(a) . We use these differentially expressed genes in studying their biological relevance, which is discussed in Sec. V.
D. Demonstrating the Unsuitability of k-Means Clustering
We set out to demonstrate that the data-driven clustering approach is better suited for observing mixtures in the distribution of gene expressions. We first normalized (centering followed by scaling) the baseline and the metformin-treated cells, which still keeps the original variability in the data. Normalizing the data rendered the data normally distributed with zero mean and unit variance. We looked to see if we could identify the downregulated genes in metformin-treated cell clusters obtained using the k-means clustering algorithm. The k-means clustering algorithm is an iterative algorithm that assigns a data point to a cluster that minimizes the distance from the point to the cluster's mean [27] . After performing the clustering, we mapped the cluster labels with the cells and their associated expression levels from before normalizing. Fig. 5(a) shows the baseline and metformintreated cell clusters with the expression of genes that are downregulated in M2, but upregulated in all other clusters; the downregulation is not visually observable, but is statistically significant (p-value< 0.05). However, Fig. 5(b) shows that for the same number of baseline and metformin-treated cell clusters, the clusters comprising the cells were different enough that we do not observe any significant variations in the average gene expressions of the downregulated genes identified by MiMoSA. We then increased the number of clusters (k) in metformin-treated cells from 3 to 7, and in all of these cases, we did not observe any clusters that could capture the same 6 cells of M2 found by MiMoSA. Therefore the downregulation was not observed in any of the clusters across the different values of k, as can be seen in Figs. 5(c)-5(f).
1) k-Means Clustering of Cells Using Only Downregulated
Genes: Instead of clustering cells using genes among those with the highest variance in their expression, we attempted to cluster the metformin-treated cells using only the downregulated genes identified by MiMoSA. When we started with k = 2 as the initial value, we observed that cluster K 2 was created with only one cell in it with some evidence of downregulated genes as observed in M2. Since the cluster was made up of only one cell, making any further analysis statistically underpowered. To find out whether the six cells of M2 would be captured together, we increased k from 2 to 9. As illustrated in Fig. 6 , none of the clusters captured the behavior observed in M2 that was identified by MiMoSA, while the same single-cell (in K 2 in k = 2) continued to be clustered by itself in K 2 (k = 2:6) and in K 1 (k = 7:9).
2) A Semi-Supervised Approach to k-Means Clustering:
Unlike unsupervised learning where no labeled data is used to infer clusters, semi-supervised learning uses a small fraction of the overall data to guide the clustering behavior [28] . We chose 3 cells (50% of M2) from each of the metformin-treated cell clusters identified by MiMoSA. Using a semi-supervised k-means clustering approach proposed by Jain [29] , we obtained three clusters of cells. The semi-supervised approach also failed to cluster the six cells of M2 together, which meant that we still could not observe the drastic downregulation observed using MiMoSA.
All these results show that if single-cell subpopulations are identified based on subtle variations in their gene expressions, a data-driven model-based unsupervised learning method could be better suited than k-means clustering algorithm.
V. UNSUPERVISED LEARNING INFORMS BIOLOGY
Pathway analysis was performed using the differentially expressed genes to further understand the biological relevance of the differentially expressed genes. The top pathways (and the associated p-values) were oxidative phosphorylation (3.8E −21), the citric acid (TCA) cycle (2.1E −19), and respiratory electron transport and mitochondrial translation (1.4E − 07). These pathways are relevant in the context of metformin in several ways.
1) The possibility of chemo-prevention with metformin is being investigated by targeting the oxidaptive phosphorylation pathway [8] .
2) It has been shown that metformin inhibits cancer cell proliferation by regulating the TCA cycle [7] . 3) Metformin has been shown to target mitochondrial metabolism in cancer therapies [9] , [10] . It is clear that the differentially expressed genes inferred from MiMoSA's clusters are on pathways known to have anticancer effects driven by metformin. Among these differentially expressed genes in the above listed pathways, we have identified the following genes that are implicated in anticancer mechanisms.
1) NDUFB9 is an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I), and loss of NDUFB9 promotes MDA-MB-231 cells proliferation, migration, and invasion; because of elevated levels of reactive oxygen species (ROS) [30] . 2) COX5B is a peripheral nuclear-encoded sub-unit of CcO (cytochrome c oxidase), and loss of COZ5B induces mitochondrial dysfunction and subsequently leads to suppression of cell growth and cell senescence [31] . 3) MRPS7 is a mitochondrial ribosomal protein, involved in mitochondrial translation, that is significantly elevated in human breast cancer cells, leading to amplified mitochondrial biogenesis and/or mitochondrial translation in epithelial breast cancer cells [32] . Therefore, mitochondrial biogenesis could be a potential target for anticancer agents and therefore could explain the retrospective success of metformin, which prevents the onset of nearly all types of cancer in diabetic patients, likely because it functions as a "weak" mitochondrial poison. 4) CDC42 is known to play a role in cell migration and cell-proliferation. NDUFB9, COX5B and MRPS7 are known to play a role in anti-cancer mechanisms in breast cancer. CDC42 has been shown to be downregulated in breast cancer patients treated with metformin and is also downregulated in our study.
Cell Migration and Cell Proliferation Experimental Study
Existence of prior knowledge of CDC42's downregulation in triple-negative breast cancer patients treated with metformin led us to perform an elaborate set of laboratory experiments to study whether downregulation of CDC42 by metformin could demonstrate any anticancer properties in triple-negative breast cancer [11] . We next give an overview of the experiments as shown in Fig. 7 and then summarize the findings that are detailed in [11] . 1) Control Experiment: Baseline MDA-MB-231 cells were cultured in a transwell dish and separated by a membrane in one setting (for cell proliferation), and by a gap made by scratching in another setting (for cell migration). If we let the dish sit for 24 hours (for cell proliferation) or 48 hours (for cell migration), the cells invaded the membrane or the gap.
2) Case Experiment: Another set of MDA-MB-231 cells were cultured in another transwell dish, but this time the CDC42 was depleted in the cells (mimicking downregulation by metformin). After we let the dish sit for 24 hours (for cell proliferation) or 48 hours (for cell migration), it was observed that only a few cells whose CDC42 was depleted were able to permeate the membrane or the gap.
These findings established that downregulation of CDC42 induced by metformin inhibited cell migration and cell proliferation. Therefore, at least one new mechanism of metformin's anticancer property has been established, via the use of mixture-model-based unsupervised learning's ability to identify candidate genes.
Future work based on the current findings will include the following.
1) We will investigate what makes the six metformintreated cells "diagnostic" in terms of inferring metformin's response, as these cells seem to be more sensitive to metformin than the other cells. 2) We will conduct laboratory experiments for the remaining candidate genes identified in this work based on their differential expression after metformin treatment and their biological relevance as shown by pathway analysis.
VI. CONCLUSION
Using metformin and TNBC as a case study, this work demonstrates an end-to-end workflow whereby learning methods can augment the drug and disease knowledge of pharmacogenomics experts by identifying biomarkers of novel drug actions. Considering that TNBC currently has no targeted treatments, this work represents an important step towards the design of targeted therapies for treating this aggressive cancer in women. Identification of a few novel and biologically significant candidates for laboratory experiments in the absence of a priori knowledge is important given the large size of the human genome and limitations in costs of laboratory experiments. The broader impact of this work in identifying a small set of differentially expressed genes after drug treatment lies in its potential to augment the drug and disease knowledge of pharmacogenomics expert, to support laboratory investigations, and thereby help establish novel biological mechanisms associated with drug response in diseases beyond triple-negative breast cancer.
